Shanghai Securities News (Reporter Weiping Song) — During the 6th CIIE, AbbVie Inc., one of the top five research-based biopharmaceutical companies in terms of global revenue, signed a strategic cooperation memorandum with the Global Procurement and Supply Chain Service Center of Sinopharm Group Co., Ltd. (hereinafter referred to as "Sinopharm Global Procurement Center"). The aim is to leverage their respective strengths to collaborate in multiple areas, including improving the accessibility of innovative drugs, comprehensive patient management throughout the disease course, enhancing patients' disease awareness, ensuring medication safety and pharmaceutical services, and exploring integrated disease solutions. These efforts will enhance patients' overall quality of life and jointly contribute to the realization of the "Healthy China 2030" goals.
The cooperation between the two parties this time, in addition to relying on the SPS+ professional pharmacy layout of Sinopharm Group Co., Ltd., will further enhance the accessibility of innovative drugs. It will also explore standardized patient management models, including providing patients with reasonable and safe medication guidance, long-term disease management, and science popularization education, thereby improving patients' disease management capabilities and quality of life. Take atopic dermatitis (AD) as an example. AD is a disease characterized by chronic recurrent itching and polymorphic inflammatory skin lesions. Its features include repeated severe itching, which can lead to cracked, scaly, and oozing skin, seriously affecting the quality of life. AD patients lack a comprehensive understanding of the causes, treatment, and management of the disease. The use of disease-related assessment tools is relatively limited, and doctors have short consultation and education times, making it urgent to carry out effective disease management work. Based on this, the two parties will explore standardized AD patient management models and provide diversified patient support, such as medication guidance, follow-up management, and disease knowledge education, promoting the standardization of AD diagnosis and treatment, building an AD whole-process management system, and helping more patients achieve an "itch-free life." In addition, the two parties will also cooperate in ensuring reasonable and safe medication use, enhancing the service capabilities of professional pharmacists, and providing patients with comprehensive disease solutions.
AbbVie Vice President and General Manager of AbbVie China, Lily Dong, stated that Sinopharm Group Co., Ltd., as a leading pharmaceutical commercial company in China, possesses abundant resources and strong channel coverage capabilities. "We are highly anticipating advancing more innovative businesses through our collaboration with Sinopharm, working together to provide patients with comprehensive disease solutions, fully accelerating the accessibility of innovative drugs, exploring full-course patient management, expediting the development of China's pharmaceutical market, and bringing profound impact to patients and society."
Liu Yong, Executive Director and President of Sinopharm Group Co., Ltd., stated that the theme of AbbVie's booth at the 6th CIIE, "Chasing the Light with Love, Illuminating Life," reflects a pharmaceutical company’s dedication and responsibility to patient-centered care. It also showcases a vision for improving people’s quality of life and adding brilliance to life. This aligns closely with Sinopharm’s philosophy of "Protecting Life, Caring for Health." As an important partner of AbbVie in China, we are confident in joining hands with AbbVie to fully leverage our integrated service advantages. Relying on a nationwide distribution network across China, we will assist AbbVie in enhancing channel coverage and increasing drug accessibility. At the same time, through the integrated management of specialty pharmacies, we will continuously innovate service models to better help patients manage their medications. Both parties will utilize brand and resource strengths to provide high-quality drugs and professional services to patients.